Chronic Cough: How to Help the Patient?
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Cough is one of the most important symptoms and it is a characteristic for many lung diseases. It often reduces the patient's quality of life. The article presents positive results of studies of the effect on mucociliary clearance, efficacy and safety of using the drug GeloMyrtol® Forte for the prevention and treatment of acute and chronic diseases of the upper and lower respiratory tract. Good tolerability allows you to help patients not only with acute but also with a chronic cough.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Favre L., Dreher T. Leuenberder P. Chronic cough: practical aspects // Rev. Med. Suisse. 2006, Nov 15; 2(87): 2605-2609.
Зайцева О.В. Муколитическая терапия в комплексном лечении болезней органов дыхания у детей // Consilium medicum. Педиатрия. – 2002. – Т. 5, № 10.
Рязанцев С.В. Принципы этиопатогенетической терапии острых синуситов: Метод. рекомендации. – М., 2003. – 33 с.
Рязанцев С.В. Роль муколитических, секретолитических и секретомоторных препаратов в лечении острых и хронических синуситов у детей // Новости оториноларингологии и логопатологии. – 2002. – № 1 (29). – С. 129-132.
Рязанцев С.В. Секретолитическая и секретомоторная терапия острых и хронических синуситов // Новости оториноларингологии и логопатологии. – 1998. – № 4 (16). – С. 90-92.
Behrbohm H., Kaschke O. The influence of the plant-derived secretolytic Gelomyrtol forte on muccocliary clearance in the maxillary sinus Laryngo-Rhino-Otologie 74 (1995). – Р. 733-737.
Ferderspiel P. et al. Efficacy of Myrtol Standardized in the therapy of acute sinusitis Laryngo-Rhino-Otologie, 76 (1997). – P. 23-27.
Matthys H. et al. Efficacy and tolerability of Myrtol Standardized in acute bronchitis – A multi centre, randomized, double-blind, placebo-controlled parallel group clinical trial vs. Cefuroxime and Ambroxol Drug Research 50 (II), 8 (200). – P. 700-711.
Stussak G. et al. Treatment of chronic sinusitis Experiences with essential oils ZfA 63, N29 (1987). – P. 869-871.
Champeroux P&Maurin A, Centre de Recherches Biologiques (France), Myrtol standardisiert Dokumentation 1996.
Beuscher N, Bien E, Elstner EF, Kietzmann M, and Amon UE, Myrtol standardized in treatment of sinusitis and bronchitis – Pharmacodynamics and pharmacokinetics, Zeitschrift für Phytotherapie, Abstractband Kongress der Gesellschaft für Phytotherapie 1997, Seiten 9–10.
App EM, Stellenwert der Mukusclearance fьr das Bronchialsystem – Pathophysiologie und therapeutische Ansätze, in: Meister R, Entzündliche Erkrankungen des Bronchialsystems, Springer Verlag, 1. Auflage 2000, Seiten 27–53.
Tomkiewicz RP, App EM et al., Pulm. Pharmacol. (1995) 8: 259-265.
Lenders H et al., Suitability of various methods as pharmacodynamic models for the investigation of the efficacy of mucolytic agents on the maxillary sinus, Naunyn-Schmiederberg’s Arch. Pharmacol. (1996) 353 (Suppl.) R151.
Lenders H, Pharmakodynamische Nachweismethoden zur Wirkung von dtherischen Цlen am oberen Respirationstrakt, in Mees K, Die unspezifische RhinoSinusitis, Springer Verlag, 1. Auflage 1996, Seiten 40–51.
Federspil et al. Efficacy of Myrtol standardized in the Therapy of Acute Sinusitis – Results of Double-Blind, Randomized, Placebo-Controlled Multicentric Study. Laryngo-Rhino-Otol. (1997) 76: 23-27.
Gillissen et al. A multi-centre, randomised, double-blind, placebo-controlled clinical trail on efficacy and tolerability of GeloMyrtol® forte in acute bronchitis. Drug Res. (2013) 63, 19-27.
